Broadly recognized and respected on Wall Street as "the entrepreneur's consultant," Jim has spent the past 40 years helping Chief-level executives successfully identify, tackle and overcome a myriad of business and financial challenges inherent to transforming emerging growth companies into enduring, world class enterprises. As Chairman, President and CEO of Hanover International, a Company Jim founded in 1990 with offices currently operating in New York, Los Angeles and San Francisco, he has advised more than 300 micro-, small- and mid-cap companies with defining and implementing their respective debt/equity capital formation, mergers and acquisitions and institutional shareholder relations strategies.
Beginning in the late 1970s, Jim served as National Sales Manager of Citicorp's (now CitiGroup's) Capital Markets Group, where he was involved in a number of prolific merger and acquisition transactions, including those comprising of such notables as Prudential-Bache, Carnation-Nestle and Beatrice-Esmark. In fact, during his tenure with Citicorp, Jim was responsible for closely collaborating with the senior leadership of many industry leading companies, crafting and executing tactical investor relations initiatives and capital raising events on their behalf. Included among his impressive clients were Levi-Strauss, Hilton Hotels, Atlantic Richfield, MCA-Universal, Litton Industries, Merrill Lynch, TransAmerica Corp., and many others.
In 2007, Jim was elected to the Board of Directors of the National Investment Banking Association (NIBA), and in June 2011 was named Chairman. NIBA is a not-for-profit association comprised of nearly 9000 national, regional and independent broker-dealers, investment banking firms, investment advisors and related capital market service providers. Since its founding, NIBA's members have been responsible for approximately 90% of all Initial Public Offerings under $20 million; and have successfully completed more than 1000 equity offerings, raising more than $40 billion in new capital for emerging growth companies. Today, NIBA members represent over $100 billion in assets under management.
John Jay Schwartz, Ph.D., is a successful academic researcher at Harvard and MIT, VC-backed entrepreneur, business mentor, consultant, and investor. Dr. Schwartz has a demonstrated track record of identifying and driving commercially viable, early-stage technologies through initial funding to clinical development and on to acquisition. His experience includes more than 30 years of entrepreneurship, technical development, funding and the commercialization of drugs, medical devices, combination products, diagnostics, regulatory/clinical strategy, IP strategy, reimbursement strategy, and orphan drugs. Dr. Schwartz has significant business development experience having negotiated and closed multiple collaborative development, supply, and license agreements. Cofounding and exiting Adnexus to BMS >$500M, $35M Millipore angel investor/Advisor to company purchased by MERCK $500M largest angel exit to that date, AcuityBio purchased by Cook Biotech. 22yr business Mentor MIT Venture Mentoring Service and as NSF ICorps instructor and former Executive Partner at NaviMed Capital.
With over 19 years' experience in public and investor relations, Kathy brings Hanover International honed leadership and proven business skill as an accomplished logistical taskmaster and workflow processes innovator. Kathy is responsible for managing and guiding all operational and logistical details and strategies related to Hanover's clients' respective campaign initiatives; while also providing the leadership, management and vision necessary to ensure that Hanover and its many clients adhered to best industry practices and compliant administrative and reporting activities. More specifically, Kathy oversees all aspects of Hanover's administrative operations, which include provision of client services that ranged from shareholder and investor relations; public relations; financial roadshow planning, booking and implementation; preparation and processing of press releases; design and development of required collateral materials; and assisting with SEC compliance and reporting, among other essential duties. Kathy also lends event planning and implementation support to the National Investment Banking Association, which hosts multiple large conferences in major U.S. financial centers each year.
Over the past two decades, FitzGerald, Yap & Kreditor Partner, Lynne Bolduc, has established herself as one of the premier corporate and securities lawyers in California. She has structured and implemented over $1 billion in financings, and has represented both domestic and international clients in complex transactions across multiple industries. She represents both private and public companies, as well as investment bankers and broker/dealers. Lynne's experience includes: entity selection and formation matters for businesses just getting started; contract negotiations; review, and drafting, mergers and acquisitions; private offerings; public offerings; and public company reporting with the Securities and Exchange Commission. Lynne is a member of the Board of Directors for the National Investment Banking Association, a not-for-profit association for national, regional and independent broker dealers, investment banking firms, investment advisors, and related capital market service providers.
Andrea Cataneo is a partner in MSK's Corporate & Business Transactions Practice Group in the firm's New York office, and a member of the Capital Markets & Securities, Alcohol Beverage Industry, and Crypto Assets & Blockchain Technology teams as well.
Andrea's practice focuses on preparing companies for capital raises, structuring secured and unsecured equity and debt financing transactions for early and late stage companies, and taking private companies public via self-registration statements and IPOs. Additionally, through her extensive relationships in the investment banking community, Andrea offers her clients introductions to targeted sources of capital.
She represents publicly-held companies with respect to 1934 Act reporting obligations to the Securities and Exchange Commission, and performs a variety of corporate transactions for her clients, including mergers and acquisitions, joint ventures, proxy contests, restructurings and corporate governance, NASDAQ and NYSE-American listing applications and all related compliance matters. Her practice covers domestic and international transactions, and she has been active in Italy, Mexico, Argentina, Canada, China, Israel and Kenya. Andrea has also been a leading voice in the Cannabis space, helping private and public clients navigate the developing legal landscape.
Andrea serves on the Boards of Together1Heart Foundation and the National Investment Banking Association.
Robert K. Gardner is the founding partner of New World Technology Partners (NWTP) – a collaboration of engineering, financial and government leaders incubating strategic technologies and ventures at the intersection of business and public policy.
He has been a leader in cyber and critical infrastructure risk management technology and an incubator of entrepreneurial enterprises since the seventies. He managed/participated in the launch of several development stage companies, including August Systems, Verdix, Meiko Scientific, Cryptek, Phoenix Numeric, Probity Labs and Location-Sentry.
Prior to forming NWTP, he held senior engineering and technical marketing positions for ILLIAC IV, PEPE, LDSP and NASF supercomputer projects at Burroughs Corporation.
He writes, speaks and has prepared testimony for the U.S. House of Representatives and Senate caucuses on the Enterprise impact of cyber risk.
Gardner has a BSEE from Rensselaer Polytechnic Institute and studied graduate system engineering and business administration at Penn State and the University of Santa Clara respectively.
Michael has spent over 30 years in the automotive industry as a sales engineer and program manager. His work experience includes the handling all aspects of product development, including manufacturing, sale negotiations and product delivery for new technologies to both the American and Japanese suppliers.
In addition to the auto industry, Michael has worked with component suppliers to sell their products. By setting up manufacturer representative territories through negotiated contracts, training and sales calls, Michael was able to reach and sell to appliance, medical, contract manufacturers and startups nationally.
Jerry Lindberg has acquired substantial expertise as a consultant, adviser and former litigating attorney with the United States Department of Justice and in the private sector. He has served as board member and CFO of publicly traded companies, business adviser and consultant, capital acquisition director, and operations officer to real world and Internet start-ups and helped raise capital for start-ups, small and microcap businesses in both the public and private sectors. His experience includes business plan preparation, early stage advising for corporate development and positioning for capital raising including crowd funding, private placement memoranda, investor presentation development, equity, debt and hybrid funding, form preparation and filing, offering syndicate coordination, sales/ marketing strategy along with investment community relations and investor relations, business development, licensing management, and assuring compliance with Federal and state regulations and fraud prevention software development. His areas of specialty include technology and intellectual property management, digital entertainment, media and marketing, eCommerce, m-Commerce, software design and development.
Don has over 30 years of capital markets experience on Wall Street. Don is the Founder and CEO of Consilium Global Research and with its staff of a dozen senior Wall Street analysts, the Company provides research coverage and advisory services to public and private companies. Don's experience includes: Managing Director at Shearson Lehman, Managing Director at Raymond James for 15 years and Managing Director, Head of Institutional Sales at Jesup & Lamont and CK Cooper.
An entrepreneurial, innovative leader with 18+ years of experience contributing to the successful development of cutting-edge products, ranging from cosmetics to diabetes glucose monitors. Inventor of more than 30 PCT US, and Chinese patents. Skilled at architecting targeted and feasible strategies and visions for startup companies, forging relationships with key partners and investors using exceptional networking and closing skills. Catalyze innovative product and program development and turnabout by quickly defining effective strategy and direction, leading teams to complete implementation, and persuading investors to support strategic growth.
Core competencies include:
• Biotech and Medical Devices
• Fundraising & Capital Formation
• Product Development
• IoT Technology
• Innovation & Patenting Process
• Venture Investment
• Startup Technical Due Diligence
• Startup Vision Development
• Entrepreneurship
• Networking & Relationship Building
Christina Valauri is a business strategy advisor, consultant and mentor to growing and pre-revenue stage innovative technology companies and their C-suite management teams and is an investor and advisory board member of several early-stage companies. She has a proven track record identifying early-stage technology driven companies with successful business models, which reflects her years of experience vetting private healthcare companies and conducting equity securities research on public pharma, biotech and med-tech companies, and has had extensive involvement in IPOs and secondary offerings. For over 30 years, she held senior analytical and management roles as broker dealer manager, operating committee member, director of U.S. and global equity research, and senior biomedical analyst, at bulge bracket and boutique institutional investor focused Wall Street firms that include ING, Credit Lyonnais (acquired by Credit Agricole), Natixis, as well as Cantor Fitzgerald, where she was the Global Director of Research. As a director of research, she developed and implemented institutional investor focused industry research strategies, built and managed teams of equity research analysts located in the US and Internationally, and developed policies and procedures that ensured adherence to security regulations and best practices.
Ms. Valauri was a senior sell-side equity research analyst for over 16 years covering leading-edge technology companies within the biotechnology, and medical technology sectors in the US and internationally. She has been recognized by The Wall Street Journal’s “Best on The Street” All Star Analyst Survey and has received the Award for Excellence - Medical Education Public Affairs Association of American - Medical Colleges - New York University. Ms. Valauri is a senior mentor at Weill Cornell Medicine BioVenture Entrepreneur Lab (eLab) and is an Astia.org advisor. Cornell University MBA Class 2020, Emerging Markets Institute (EMI) Fellow President 2020, Reed College B.A. Biology. Certificates: eCornell: Healthcare Change Management, Project Management, Systems Thinking, Digital Leadership, Digital Innovation; Oxford University, Fintech; University of California, Berkeley/Haas School of Business, Social Leadership.
You can fill out a form at our
contact page
or
email us directly at
ka@hanoverintlinc.com
